- Service Name
Mesoblast
- Industry
Biotechnology, regenerative medicine, cellular therapies, allogeneic medicines
- Main Value Proposition
Mesoblast offers advanced cellular therapies that provide effective treatment options for patients with complex inflammatory diseases, leveraging a unique technology that allows for broad applicability without the need for immune suppression.
- Description
Mesoblast is a biotechnology company focused on developing innovative allogeneic cellular medicines using its proprietary mesenchymal lineage cell technology platform. The company aims to treat complex inflammatory diseases that are resistant to conventional standard care.
- Key Features
Proprietary mesenchymal lineage cell technology platform; Allogeneic product candidates that do not require donor-recipient matching; Industrial scale manufacturing of cell therapies; Portfolio of Phase 3 product candidates targeting serious conditions
- Use Cases
Mesoblast's therapies are particularly valuable in treating conditions such as steroid-refractory acute graft versus host disease, acute respiratory distress syndrome due to COVID-19, chronic heart failure, and chronic low back pain.
- Competitive advantages
Ability to administer therapies without donor matching or immune suppression; Focus on complex inflammatory diseases with unmet medical needs; Strong pipeline of Phase 3 candidates and next-generation technologies
- Strengths
Mesoblast's strengths lie in its innovative technology platform, a robust pipeline of clinical candidates, and the ability to manufacture therapies at scale, which enhances accessibility and potential market impact.
- Positioning
Mesoblast positions itself as a leader in regenerative medicine, focusing on advanced cellular therapies that address significant health challenges.
- Audience
The primary target users include healthcare providers, patients with complex inflammatory diseases, and investors interested in innovative biopharmaceutical solutions.
- CTA
Learn more about our product candidates
- Tags
cell therapy
regenerative medicine
biotechnology
inflammatory diseases
- Tagline
Innovative allogeneic cellular medicines to treat complex inflammatory diseases.
- Tone of Voice
Innovative, authoritative, compassionate
- Differentiation
Mesoblast's use of mesenchymal lineage cells, which are rare and can be expanded for industrial-scale production, sets it apart from competitors who may rely on more conventional cell therapy approaches.
- Brand Positioning
The brand is identified as a pioneering force in the field of regenerative medicine, emphasizing innovation, scientific rigor, and a commitment to improving patient outcomes.
- Founded
2004-01-01
- Founders
Michael Schuster
Silviu Itescu